161 related articles for article (PubMed ID: 29110847)
1. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
Hochmair MJ; Schwab S; Burghuber OC; Krenbek D; Prosch H
Lung Cancer; 2017 Nov; 113():4-6. PubMed ID: 29110847
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.
Guibert N; Mazieres J; Delaunay M; Casanova A; Farella M; Keller L; Favre G; Pradines A
Oncotarget; 2017 Jun; 8(23):38056-38060. PubMed ID: 28445137
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.
Reck M
Immunotherapy; 2018 Feb; 10(2):93-105. PubMed ID: 29145737
[TBL] [Abstract][Full Text] [Related]
4. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study.
Reck M; Taylor F; Penrod JR; DeRosa M; Morrissey L; Dastani H; Orsini L; Gralla RJ
J Thorac Oncol; 2018 Feb; 13(2):194-204. PubMed ID: 29129758
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
6. Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis.
Abdel-Rahman O
Clin Respir J; 2018 May; 12(5):1809-1819. PubMed ID: 29115057
[TBL] [Abstract][Full Text] [Related]
7. Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.
Li SD; Martial A; Schrock AB; Liu JJ
Exp Hematol Oncol; 2017; 6():29. PubMed ID: 29142786
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
Cancer Med; 2018 Jan; 7(1):13-20. PubMed ID: 29150906
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F
Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121
[TBL] [Abstract][Full Text] [Related]
10. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
[TBL] [Abstract][Full Text] [Related]
11. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
Wang DY; Ye F; Zhao S; Johnson DB
Oncoimmunology; 2017; 6(10):e1344805. PubMed ID: 29123955
[No Abstract] [Full Text] [Related]
12. Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials.
Ramos-Esquivel A; van der Laat A; Rojas-Vigott R; Juárez M; Corrales-Rodríguez L
ESMO Open; 2017; 2(3):e000236. PubMed ID: 29181191
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in non-small-cell lung cancer with EGFR mutation.
Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Funazo T; Hirai T
Ann Oncol; 2018 Mar; 29(3):777-778. PubMed ID: 29161357
[No Abstract] [Full Text] [Related]
14. Biomarkers for immunotherapy in bladder cancer: a moving target.
Aggen DH; Drake CG
J Immunother Cancer; 2017 Nov; 5(1):94. PubMed ID: 29157296
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Tanizaki J; Haratani K; Hayashi H; Chiba Y; Nakamura Y; Yonesaka K; Kudo K; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Ito A; Nakagawa K
J Thorac Oncol; 2018 Jan; 13(1):97-105. PubMed ID: 29170120
[TBL] [Abstract][Full Text] [Related]
18. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
19. Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab.
Johnson DY; Short RG; Patz EF
Clin Lung Cancer; 2018 Mar; 19(2):175-180. PubMed ID: 29153896
[TBL] [Abstract][Full Text] [Related]
20. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.
Dong ZY; Zhang JT; Liu SY; Su J; Zhang C; Xie Z; Zhou Q; Tu HY; Xu CR; Yan LX; Li YF; Zhong WZ; Wu YL
Oncoimmunology; 2017; 6(11):e1356145. PubMed ID: 29147605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]